{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:08:49Z","timestamp":1740146929316,"version":"3.37.3"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010806","name":"Amgen Nederland","doi-asserted-by":"publisher","award":["grant no. 315542"],"award-info":[{"award-number":["grant no. 315542"]}],"id":[{"id":"10.13039\/100010806","id-type":"DOI","asserted-by":"publisher"}]},{"name":"isala klinieken","award":["grant no.1907"],"award-info":[{"award-number":["grant no.1907"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Multiple myeloma (MM) is the second most common hematologic malignancy. MM is associated with significant morbidity due to its end-organ destruction and is a disease of the older population. Although survival rates for MM have improved over the last decade, due to an increase in treatment options, the disease remains incurable. Expensive (oral) agents are widely used in MM patients; however, tools for supporting patients in complex treatment regimens are scarce. To investigate if a tool will support MM patients and healthcare professionals, the MM e-coach was developed and tested. The aim of this study is to study the impact of telemonitoring on adherence, complications and quality of life in patients with MM (ITUMM study).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A two-arm open-label parallel-group randomized controlled trial will be conducted between March 2021 and June 2024 to compare the telemonitoring (MM e-coach) with standard MM care. This study aimed to recruit 150 patients with recently diagnosed multiple myeloma (RDMM), starting first or second line of treatment. Blinded primary outcome is adherence by pill count after start of treatment at 1\u20133 months. Secondary outcomes are patient reported outcomes: GFI, EQ-5D-5L, EORTC-QLQ-C30, SDM-Q-9, MARS-5, single item questions, PREMs, adverse events, OS and PFS. Patient reported outcomes were developed and integrated in the e-coach MM to regularly measure digitized outcomes of MM patients from time of RDMM until 12 months post-diagnosis. Online measurements will be performed at baseline (0), 3, 6, 9 and 12 months.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>Ethics approval has been granted by the Ethics Committee of the Isala klinieken in The Netherlands (No. 201111) at 25 February 2021. Study results will be disseminated to the relevant healthcare communities by publication in peer-reviewed journals, and at scientific and clinical conferences.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Study registration number<\/jats:title>\n<jats:p>ClinicalTrials.gov number: NCT05964270 and ABR number: NL75771.075.20.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0307177","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T18:14:35Z","timestamp":1724696075000},"page":"e0307177","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of telemonitoring on correct drug use, complications and quality of life among patients with multiple myeloma (ITUMM): A study protocol for an open-label, parallel-group, randomized controlled trial"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-0789","authenticated-orcid":true,"given":"Job F. H.","family":"Eijsink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A. F.","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Kamminga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille A.","family":"Edens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Gerard","family":"Maring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G. J.","family":"ter Horst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"issue":"6","key":"pone.0307177.ref001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival, a unique malignancy.","volume":"43","author":"D. Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"10272","key":"pone.0307177.ref002","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma.","volume":"397","author":"NWCJ van de Donk","year":"2021","journal-title":"The Lancet"},{"issue":"9","key":"pone.0307177.ref003","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"AJ Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"pone.0307177.ref004","unstructured":"Multipel myeloom. [cited April 17, 2023]. Available from: https:\/\/iknl.nl\/kankersoorten\/hemato-oncologie\/nkr-cijfers\/mm"},{"issue":"3","key":"pone.0307177.ref005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"MA Dimopoulos","year":"2021","journal-title":"Annals of Oncology"},{"issue":"Suppl 1","key":"pone.0307177.ref006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: Every year a new standard?","volume":"1","author":"SV Rajkumar","year":"2019","journal-title":"Hematol Oncol."},{"issue":"7","key":"pone.0307177.ref007","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"C Pawlyn","year":"2019","journal-title":"Blood"},{"issue":"1","key":"pone.0307177.ref008","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1002\/ajh.26602","article-title":"Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis","volume":"98","author":"MA Dimopoulos","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"pone.0307177.ref009","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bjh.18654","article-title":"Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies","volume":"200","author":"D Minakata","year":"2023","journal-title":"Br J Haematol"},{"issue":"S1","key":"pone.0307177.ref010","first-page":"S3","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"1","author":"U Goel","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"pone.0307177.ref011","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"MA Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"pone.0307177.ref012","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jama.2020.16467","article-title":"New T-Cell Therapy Tested for Multiple Myeloma","volume":"324","author":"J. Abbasi","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"pone.0307177.ref013","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1001\/jama.2021.6401","article-title":"Cell-Based Gene Therapy Is New Option for Multiple Myeloma","volume":"325","author":"R. Voelker","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"pone.0307177.ref014","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-019-0804-4","article-title":"Management of Newly Diagnosed Elderly Multiple Myeloma Patients.","volume":"21","author":"C Antoine-Pepeljugoski","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"pone.0307177.ref015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clml.2021.11.003","article-title":"SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma.","volume":"22","author":"SJ Grant","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"5","key":"pone.0307177.ref016","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/ACM.0000000000003122","article-title":"Defining and Implementing Value-Based Health Care: A Strategic Framework.","volume":"95","author":"E Teisberg","year":"2020","journal-title":"Academic Medicine."},{"key":"pone.0307177.ref017","doi-asserted-by":"crossref","first-page":"121072","DOI":"10.1016\/j.techfore.2021.121072","article-title":"Managing shifts to value-based healthcare and value digitalization as a multi-level dynamic capability development process","volume":"172","author":"DO Kokshagina","year":"2021","journal-title":"Technol Forecast Soc Change"},{"issue":"1","key":"pone.0307177.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737167.2023.2136168","article-title":"Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions.","volume":"23","author":"JFH Eijsink","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"pone.0307177.ref019","first-page":"129","article-title":"The use of patient-reported outcome and experience measures for health policy purposes: A scoping review in oncology.","author":"E Minvielle","year":"2023","journal-title":"Health Policy"},{"issue":"1","key":"pone.0307177.ref020","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-019-4646-4","article-title":"The acceptance and applicability of a patient-reported experience measurement tool in oncological care: a descriptive feasibility study in northern Germany.","volume":"19","author":"C Rudolph","year":"2019","journal-title":"BMC Health Serv Res."},{"issue":"1","key":"pone.0307177.ref021","doi-asserted-by":"crossref","DOI":"10.1186\/s40814-023-01307-0","article-title":"Rationale and development of an e-health application to deliver patient-centered care during treatment for recently diagnosed multiple myeloma patients: pilot study of the MM E-coach.","volume":"9","author":"P Geerts","year":"2023","journal-title":"Pilot Feasibility Stud"},{"issue":"6","key":"pone.0307177.ref022","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3322\/caac.21727","article-title":"Oncologic emergencies and urgencies: A comprehensive review","volume":"72","author":"BE Gould Rothberg","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"pone.0307177.ref023","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/CCI.20.00145","article-title":"Digital Health for Patients With Multiple Myeloma: An Unmet Need.","author":"S Jagannath","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"issue":"6","key":"pone.0307177.ref024","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.","volume":"34","author":"E Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0307177.ref025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2015.64.9491","article-title":"PRO-cision Medicine: Personalizing patient care using patient-reported outcomes","volume":"34","author":"RE Jensen","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"pone.0307177.ref026","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2016.67.7708","article-title":"Symptom improvement requires more than screening and feedback","volume":"34","author":"K Kroenke","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"pone.0307177.ref027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08527-8","article-title":"The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences","volume":"21","author":"C Pritlove","year":"2021","journal-title":"BMC Cancer"},{"issue":"22","key":"pone.0307177.ref028","doi-asserted-by":"crossref","first-page":"8040","DOI":"10.1002\/cam4.4322","article-title":"Trust and shared decision-making among individuals with multiple myeloma: A qualitative study","volume":"10","author":"RL Whitney","year":"2021","journal-title":"Cancer Med"},{"key":"pone.0307177.ref029","unstructured":"Measure Outcomes & Cost for Every Patient\u2014Institute For Strategy And Competitiveness\u2014Harvard Business School. [citedApril 27, 2023]. Available from: https:\/\/www.isc.hbs.edu\/health-care\/value-based-health-care\/key-concepts\/Pages\/measure-outcomes-and-cost.aspx"},{"journal-title":"Adherence to Long-Term Therapies: Evidence for Action","year":"2003","author":"World Health Organization","key":"pone.0307177.ref030"},{"issue":"10","key":"pone.0307177.ref031","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.clml.2022.05.003","article-title":"Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis.","volume":"22","author":"AY Naser","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"7","key":"pone.0307177.ref032","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00277-021-04543-7","article-title":"Oral therapy adherence and satisfaction in patients with multiple myeloma","volume":"100","author":"M Solano","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"pone.0307177.ref033","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clml.2019.09.618","article-title":"Adherence to lenalidomide in older adults with newly-diagnosed multiple myeloma.","volume":"20","author":"H Mian","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"pone.0307177.ref034","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","article-title":"Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma.","volume":"18","author":"S Gupta","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"3","key":"pone.0307177.ref035","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/annonc\/mdt433","article-title":"Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review","volume":"25","author":"MTE Puts","year":"2014","journal-title":"Ann Oncol"},{"issue":"5","key":"pone.0307177.ref036","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1200\/JOP.2016.019729","article-title":"Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer.","volume":"13","author":"JM Jacobs","year":"2017","journal-title":"J Oncol Pract"},{"issue":"1","key":"pone.0307177.ref037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3110-2","article-title":"Supporting adherence to oral anticancer agents: Clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists.","volume":"17","author":"L Timmers","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"pone.0307177.ref038","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s13187-013-0511-z","article-title":"Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature.","volume":"28","author":"K Patel","year":"2013","journal-title":"J Cancer Educ."},{"key":"pone.0307177.ref039","first-page":"346","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","author":"AW Chan","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"pone.0307177.ref040","doi-asserted-by":"crossref","DOI":"10.1186\/s40814-016-0105-8","article-title":"CONSORT 2010 statement: extension to randomised pilot and feasibility trials.","volume":"2","author":"SM Eldridge","year":"2016","journal-title":"Pilot Feasibility Stud."},{"issue":"6","key":"pone.0307177.ref041","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jamda.2012.04.007","article-title":"Measurement properties of the Groningen Frailty Indicator in home-dwelling and institutionalized elderly people.","volume":"13","author":"LL Peters","year":"2012","journal-title":"J Am Med Dir Assoc"},{"issue":"8","key":"pone.0307177.ref042","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jamda.2012.06.008","article-title":"Investigating Measurement Properties of the Groningen Frailty Indicator: A More Systematic Approach is Needed.","volume":"13","author":"EO Hoogendijk","year":"2012","journal-title":"J Am Med Dir Assoc."},{"issue":"5","key":"pone.0307177.ref043","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"AJ Cowan","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"pone.0307177.ref044","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1200\/JOP.17.00039","article-title":"Improved Adherence Rates and Clinical Outcomes of an Integrated, Closed-Loop, Pharmacist-Led Oral Chemotherapy Management Program.","volume":"14","author":"B Muluneh","year":"2018","journal-title":"J Oncol Pract."},{"issue":"2","key":"pone.0307177.ref045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1078155214559114","article-title":"Medication adherence to oral cancer therapy: The promising role of the pharmacist","volume":"22","author":"MA Felton","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"pone.0307177.ref046","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ecc.12124","article-title":"Adherence to oral antineoplastic agents by cancer patients: definition and literature review","volume":"23","author":"F Bassan","year":"2014","journal-title":"Eur J Cancer Care (Engl)."},{"key":"pone.0307177.ref047","article-title":"Adherence to immunomodulatory drugs in patients with multiple myeloma.","author":"A Lie Cransacid","year":"2019","journal-title":"Published online"},{"issue":"1","key":"pone.0307177.ref048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40545-021-00385-w","article-title":"Estimating proportion of days covered (PDC) using real-world online medicine suppliers\u2019 datasets.","volume":"14","author":"D Prieto-Merino","year":"2021","journal-title":"J Pharm Policy Pract"},{"issue":"10","key":"pone.0307177.ref049","article-title":"Measurement Properties of Existing Patient-Reported Outcome Measures on Medication Adherence: Systematic Review.","volume":"22","author":"YH Kwan","year":"2020","journal-title":"J Med Internet Res"},{"issue":"9","key":"pone.0307177.ref050","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00228-020-02910-3","article-title":"Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib.","volume":"76","author":"CCLM Boons","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0307177.ref051","unstructured":"Quality of Life of Cancer Patients\u2014EORTC\u2014Quality of Life: EORTC\u2013Quality of Life. [cited 11 June 2023]. Available from: https:\/\/qol.eortc.org\/questionnaire\/eortc-qlq-c30\/"},{"issue":"6","key":"pone.0307177.ref052","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","article-title":"A Comparison of the EQ-5D-3L and EQ-5D-5L.","volume":"38","author":"AJ Thompson","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"pone.0307177.ref053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173904","article-title":"Use of the 9-item Shared Decision Making Questionnaire (SDM-Q-9 and SDM-Q-Doc) in intervention studies\u2014A systematic review.","volume":"12","author":"H Doherr","year":"2017","journal-title":"PLoS One."},{"issue":"12","key":"pone.0307177.ref054","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s00277-022-04992-8","article-title":"Is comprehensive geriatric testing guiding in the identification of multiple myeloma patients who are candidates for autologous stem cell transplantation? A prospective analysis","volume":"101","author":"KD Demirel","year":"2022","journal-title":"Ann Hematol"},{"issue":"8","key":"pone.0307177.ref055","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance.","volume":"23","author":"AJ Claxton","year":"2001","journal-title":"Clin Ther"},{"issue":"4","key":"pone.0307177.ref056","first-page":"685","article-title":"How should we measure medication adherence in clinical trials and practice?","volume":"3","author":"JK Lee","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"7\u20138","key":"pone.0307177.ref057","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1345\/aph.17423","article-title":"Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly","volume":"32","author":"RE Grymonpre","year":"1998","journal-title":"Annals of Pharmacotherapy"},{"issue":"7\u20138","key":"pone.0307177.ref058","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/106002809302700705","article-title":"Pharmacists\u2019 interventions using an electronic medication-event monitoring device\u2019s adherence data versus pill counts.","volume":"27","author":"JR Matsuyama","year":"1993","journal-title":"Annals of Pharmacotherapy"},{"issue":"2","key":"pone.0307177.ref059","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12032-011-9926-8","article-title":"Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients","volume":"29","author":"JH Moon","year":"2012","journal-title":"Med Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0307177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T18:15:16Z","timestamp":1724696116000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0307177"}},"subtitle":[],"editor":[{"given":"Kathleen","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0307177","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,8,26]]}}}